云南高校图书馆联盟文献共享服务平台- RIVAROXABAN

RIVAROXABAN: 作品数：47被引量：87H指数：5; 导出分析报告; 相关作者：刘薇董金华黄河林颖刘振武更多>>; 相关机构：沈阳药科大学邯郸市中心医院温州医科大学拜耳医药保健股份公司更多>>; 相关期刊：《药学进展》《Acta Pharmacologica Sinica》《World Journal of Gastroenterology》《Pharmacology & Pharmacy》更多>>; 相关基金：国家自然科学基金浙江省重点科技创新团队项目更多>>

Macrohematuria in the Course of Rivaroxaban Therapy: A Case of Bladder Tumor: 《Open Journal of Nephrology》2024年第4期478-485,共8页Suha Al Fathima Mohamed Al Sabry Gamage Ravindi Lakma Perera Balapuwaduge Shayami Michelle Mendis Karpovich Yulia Ivanovna Karpovich Yuri Leonidovich; Background: Rivaroxaban is a directly acting, oral anti-coagulant (factor Xa inhibitor) which is used to treat and prevent the formation of blood clots. A common side effect of this drug is an increase in bleeding ten...; 关键词：Macroscopic Hematuria RIVAROXABAN Urological Malignancies (Source: MeSH NLM)

Clinical profile and outcomes in very elderly patients with atrial fibrillation anticoagulated with rivaroxaban: data from the EMIR study: 《Journal of Geriatric Cardiology》2024年第7期723-732,共10页Francisco Marín Manuel Anguita Sánchez Iñaki Lekuona Marcelo Sanmartín Fernán-dez Vivencio Barrios Carlos Perez Muñoz Juan Cosín-Sales Alejandro IPérez Cabeza Vanesa Roldán Schilling Carles Rafols Priu Esteban Orenes-Piñero María Asunción Es-teve-Pastor; EMIR Study is sponsored by Bayer; Objectives To analyze the clinical profile,adequacy of treatment with rivaroxaban and outcomes in octogenarians with atrial fibrillation(AF),taking rivaroxaban in clinical practice.Methods Observational and non-interv...; 关键词：PATIENTS ATRIAL BLEEDING

Pharmacodynamic Study of Parallel Groups Comparing the Effect of Rivaroxaban 20 Mg (Laboratorios Leti, S.A.V.) vs Rivaroxaban 20 Mg (Bayer Laboratories) on Prothrombin Time: 《International Journal of Clinical Medicine》2024年第3期123-133,共11页Elsy Rodriguez de Roa María Gonzalez Yibirin David Rincón Matute Carolina Aguilera; Background: The prevalence of both atrial fibrillation (FA) and diabetes mellitus (DM) is increasing and they often occur together and constitute a high risk of thrombosis. Rivaroxaban is a Factor Xa inhibitor with a ...; 关键词：Pharmacodynamic Study RIVAROXABAN Clinical Trial PT APTT

Effectiveness and safety of apixaban and rivaroxaban vs warfarin in patients with atrial fibrillation and chronic kidney disease: 《World Journal of Nephrology》2023年第5期132-146,共15页Sylvie Perreault Laurie-Anne Boivin Proulx Aurélie Lenglet Ziad A Massy Marc Dorais; BACKGROUND Randomized controlled trials(RCTs)of direct oral anticoagulants(DOACs)included a low proportion of atrial fibrillation(AF)patients with chronic kidney disease(CKD),and suggested that DOACs are safe and effe...; 关键词：Atrial fibrillation Chronic kidney disease Direct oral anticoagulant EFFECTIVENESS SAFETY WARFARIN

Livedoid Vasculopathy Secondary to Protein C Deficiency:A Case Successfully Treated With Rivaroxaban: 《International Journal of Dermatology and Venereology》2023年第3期175-177,共3页Nattanicha Chaisrimaneepan Tanongkiet Tienthavorn; Introduction:Livedoid vasculopathy is a chronic noninflammatory skin disease secondary to hypercoagulable states.No therapeutic guideline has yet been established for livedoid vasculopathy.We herein report a case of l...; 关键词：livedoid vasculopathy protein C deficiency RIVAROXABAN HYPERCOAGULABILITY hypercoagulable state atrophie blanche

Rivaroxaban for the treatment of heparin-induced thrombocytopenia with thrombosis in a patient undergoing artificial hip arthroplasty:A case report: 《World Journal of Clinical Cases》2023年第26期6147-6153,共7页Fang-Fang Lv Mei-Ye Li Wei Qu Zhao-Shun Jiang; BACKGROUND Anticoagulation treatment after lower limb surgery is one of the key methods to avoid thrombosis,and low-molecular-weight heparin is the treatment that is most frequently used in clinical practice.But one u...; 关键词：Low-molecular-weight heparin Heparin-induced thrombocytopenia with thrombosis PLATELET Case report

Deciding the Gold Standard for Oral Anticoagulation Therapy: 《World Journal of Cardiovascular Diseases》2023年第3期170-180,共11页Josh Fenn; Healthcare practitioners have many anticoagulant options for treating various disease states pertaining to blood clots and blood clot formation. Each anticoagulant has pros and cons and the decision of which pharmacol...; 关键词：Oral Anticoagulation NOAC VKA Gold Standard RIVAROXABAN AC Therapy

Comparison of the Safety and Efficacy of Warfarin Versus Rivaroxaban in Northern Chinese Patients with Different CHA2DS2-VASc Scores: A Retrospective Cohort Study: 《Cardiovascular Innovations and Applications》2023年第1期203-212,共10页Shiwei Xu Qi Zhao Haiyu Zhang Xianghui Li Jing Lu Hongyan Wang Yuanyuan Guo Zengxiang Dong; The study was funded by the National Natural Science Foundation of China(No.81900366);the Postdoctoral Initiation Foundation of Heilongjiang Province(LBH-Q19032);the Research Project of the First Affiliated Hospital of Harbin Medical University(2021J01).; Purpose:This study was aimed at evaluating the safety and efficacy of warfarin versus rivaroxaban in patients with atrial fibrillation(AF)and different CHA2DS2-VASc score subgroups in northern China.Methods:A retrospe...; 关键词：Atrial fibrillation WARFARIN RIVAROXABAN Ischemic stroke CHA2DS2-VASc score

Population pharmacokinetic and pharmacodynamic analysis of rivaroxaban in Chinese patients with non-valvular atrial fibrillation被引量：4: 《Acta Pharmacologica Sinica》2022年第10期2723-2734,共12页Xiao-qin Liu Yu-fei Zhang Hong-yan Ding Ming-ming Yan Zheng Jiao Ming-kang Zhong Chun-lai Ma; This project was supported by the Shanghai“Rising Stars of Medical Talent”Youth Development Program(Youth Medical Talents-Clinical Pharmacist Program);Shanghai Key Clinical Specialty Projects-Clinical Pharmacy to Ming-kang Zhong(shslczdzk06502).; Rivaroxaban, a direct factor Xa inhibitor, is widely used for stroke prevention in patients with non-valvular atrial fibrillation (NVAF). The aim of this study was to conduct a population pharmacokinetic-pharmacodynam...; 关键词：RIVAROXABAN atrial fibrillation population pharmacokinetics-pharmacodynamics model-informed precision dosing Chinese

Effect of uninterrupted dabigatran or rivaroxaban on achieving ideal activated clotting time to heparin response during catheter ablation in patients with atrial fibrillation被引量：1: 《Journal of Geriatric Cardiology》2022年第8期565-574,共10页Qian XIN Chuang ZHANG Yu-Jia WANG Jian LI Tao CHEN Shi-Xing LI Wei WANG Yu YANG Wen-Juan SONG Jin ZHOU Xiang-Min SHI; supported by the Chinese PLA Special Research on Health Care (17BJZ08); BACKGROUND Uninterrupted use of oral anticoagulants before atrial fibrillation(AF)ablation can reduce the incidence of perioperative thromboembolic events.However,the effect of new oral anticoagulants on activated clo...; 关键词：PATIENTS HEPARIN DOSAGE

RIVAROXABAN